Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
$40.15
$0.33(1.68%)
At close: 4:00 PM EST
$40.15
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$9.57 - $43.69
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.28M
Market Cap
$5.23B
Enterprise Value$2.01B
Total Cash (Recent Filing)$900.37M
Total Debt (Recent Filing)$713.29M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Nov 25, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding138,257,550
10 Day Avg. Volume1,905,381
30 Day Avg. Volume2,282,485
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)12.51
Price to Sales (P/S)653.40
P/FCF Ratio-3.84
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue3.36
Enterprise Value/Gross Profit3.48
Enterprise Value/Ebitda-38.23
Forecast
1Y Price Target
$44.71Price Target Upside11.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PreparationLaunch preparations are already complete, with payer interactions covering more than 85% of U.S. lives, and Arrowhead’s One-REDEMPLO pricing strategy anchoring long-term value in high-risk sHTG.
Regulatory ApprovalsThe FDA approved REDEMPLO (plozasiran) as the first siRNA therapy for familial chylomicronemia syndrome (FCS), marking a transformative entry into the APOC3 landscape with a best-in-class profile.
Strategic PartnershipsArrowhead announced a global license and collaboration agreement with NVS for ARO-SNCA and additional collaboration targets, which brings in additional capital and potential future revenue.
Bears Say
Competitive PositionArrowhead’s plozasiran is around 2 years behind in what could end up being a larger than expected blockbuster market opportunity.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $43.69 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $5.23B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 25, 2025 which is in 3 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.308.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 138,257,550 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went up 2.242%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.71 (11.36% Upside)
$44.71 (11.36% Upside)
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.63%
12-Months-Change
Fundamentals
Return on Equity
-34.80%
Trailing 12-Months
Asset Growth
56.22%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of serious diseases by leveraging its proprietary RNA interference (RNAi) technology. The company operates primarily in the biotechnology sector, with a focus on developing therapies for liver diseases, cancer, and other serious health conditions. Arrowhead's core product candidates include ARO-AAT for the treatment of alpha-1 antitrypsin deficiency and ARO-HBV for hepatitis B, among others, which are designed to silence specific genes implicated in disease pathology.
ARWR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Arrowhead Pharmaceuticals has made significant progress in its clinical pipeline and strategic partnerships, with several promising developments, such as the full enrollment of key studies and a substantial deal with Sanofi. However, the negative impact of Sarepta's restructuring on Arrowhead's stock price and increased operating expenses are notable concerns. The overall sentiment is cautiously optimistic, given the strong financial position and upcoming milestones.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$44.71
▲(11.36% Upside)
Technical Analysis
Ownership Overview
4.10% Insiders
17.70% Mutual Funds
6.01% Other Institutional Investors
45.61% Public Companies and Individual Investors